Biogen Idec Ma Inc.

Wyeth

Prothena Biosciences Limited

Novartis Corporation

Tanox Biosystems, Inc.

Janssen Alzheimer Immunotherapy

Chugai Seiyaku Kabushiki Kaisha

Biogen Ma Inc.

Elan Pharmaceuticals, Inc.

Elan Pharma International Limited

Neuralab Limited

Boehringer Ingelheim International Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Janssen Sciences Ireland Uc

Athena Neurosciences, Inc.

Jose William Saldanha

Tarlochan S Nijjar

Ellen A Garber

Guriq Basi

Mary M Bendig

Paul D Lyne

Michael Karpusas

Steven Tarran Jones

Dale Bernard Schenk

Alexey Alexandrovich Lugovskoy

Masayuki Tsuchiya

Koh Sato

Kenneth J Simon

Ted A Yednock

Herman Van Vlijmen

Norman Hardman

Frank Kolbinger

Olivier J Leger

Antonin De Fougerolles

Geertruida Machteld Veldman

Lioudmila Tchistiakova

Victor E Kotelianski

Samuel Goldman

Debra D Donaldson

Jonathan Wall

Theodore A Yednock

Paul H Weinreb

Xiang-Yang Tan

Kimberly Ann Marquette

Lori J Fitz

Angela Widom

Shelia Marie Violette

Laura Lin

Eric Feyfant

Carl Reid

Kevin Delos Parris

Tarran Jones

Marion T Kasaian

Louise A Koopman

Tania Shane

Ellen A Garber Stark

Amy Sze Pui Tam

Nancy L Wood

Herman W T Van Vlijmen

Wolfgang J Rettig

Scott Glaser

John Edward Park

Peter Andrew Seubert

Neil I Goldstein

S Tarran Jones

Michele Sanicola-Nadel

Xiufeng Wu

Frédérique Bard

Pilar Garin-Chesa

Uwe Bamberger

Nicholas A Giorgio

Olivier L&egrave;ger

Catherine A Kettleborough

Peter A Seubert

Tarran S Jones

Antonin R De Fougerolles

The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.

Humanized antibodies that recognize alpha-synuclein

The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.

Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.

Antibodies to VLA-1

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&#x3b2; in the brain of a patient. Preferred agents include humanized antibodies.

Humanized antibodies that recognize beta amyloid peptide

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize &#x3b1;&#x3b2;integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-&#x3b1;&#x3b2;antibodies of the invention. The invention also relates to the identification of differential expression of the integrin &#x3b1;&#x3b2;on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin &#x3b1;&#x3b2;.

[object Object]

Growing community of inventors

Enfield, United Kingdom

Jose William Saldanha